Overview

Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension

Status:
Unknown status
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
To assess the effectiveness of the synthetic analogue of prostacyclin in postembolic residual pulmonary hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Meshalkin Research Institute of Pathology of Circulation
Treatments:
Iloprost
Warfarin